Tesofensine

It pairs genuinely strong Phase 2 weight loss with a cardiovascular signal that stalled its own development and a regulatory record that never crossed the finish line. The efficacy is not in question: about 9 to 11 percent at 24 weeks, roughly double the obesity drugs of its era, per Astrup 2008, Lancet. The problem is that the same mechanism raising heart rate is the one driving the weight loss, the pivotal paper carries a journal Expression of Concern, there is no Phase 3 obesity approval, and the follow-up product had to add a beta-blocker to suppress the cardiovascular signal, per Huynh 2022. For routine obesity, an approved GLP-1 does the job with far less risk. The honest read: real weight loss, real cardiovascular and psychiatric cost, and a stalled drug.

✅ Best for: Essentially no one as a self-directed biohack. The only defensible context is a clinician-supervised setting in an approved market, or a monitored orphan-indication program like hypothalamic obesity where the metoprolol-buffered Tesomet form blunted the heart-rate signal, per Huynh 2022, in a patient who has failed or cannot use a GLP-1 drug and will accept close cardiovascular and mood monitoring. Anyone in that narrow window who can source regulated material and track resting heart rate and blood pressure relentlessly.

❌ Avoid if: You have any cardiovascular disease, hypertension, arrhythmia, or elevated resting heart rate, given the chronic tachycardia signal, per Astrup 2008, Lancet. You have any history of anxiety, mood disorder, insomnia, or substance-use disorder, given the monoamine and stimulant-class mechanism. You are pregnant or breastfeeding. You would be sourcing grey-market material of unknown purity. Or you simply want effective, safer weight loss, in which case an FDA-approved GLP-1 like semaglutide is the better-evidenced choice, and even a cautioned stimulant like bromantane sits in a different risk lane.